Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m

May 15 2018

• By Mandy Jackson

Handshake of businessmen

Related Content

Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m

Jan 19 2017

$1.6bn ARMO Buy Gives Lilly Its Most Advanced Immuno-Oncology Asset

May 11 2018

Lung cancer key for Takeda's alisertib after Ph III lymphoma flop

May 13 2015

Emergings In Brief, May 2015

May 27 2015

Related Companies

Eli Lilly and Company

CASI Pharmaceuticals, Inc.

AstraZeneca PLC

Nemucore Medical Innovations, Inc.

Otsuka Holdings Co., Ltd.

Astex Pharmaceuticals, Inc.

Amgen, Inc.

Takeda Pharmaceutical Co. Ltd.

Cyclacel Pharmaceuticals, Inc.

MabVax Therapeutics Holdings, Inc.

AbbVie Inc.

Rigel Pharmaceuticals, Inc.

Merck KGaA

Vertex Pharmaceuticals Incorporated

Merck & Co., Inc.

Pfizer Inc.

Sunesis Pharmaceuticals, Inc.

CoLucid Pharmaceuticals, Inc.

Modulate Therapeutics, Inc.

Esperas Pharma Inc.

Additional Topics

Deals Business Strategies Commercial Cancer BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window